Table 1 Patient-, disease- and therapy-related characteristics at index date ^a

Baseline patient characteristics

Sex, N (%)

 Female

308 (44.7)

156 (50.2)

115 (41.8)

37 (35.7)

Age, years, median (IQR)

66 (12.0)

59 (8.0)

69 (4.0)

78 (5.0)

BMI, kg/m², median (IQR)

24.5 (6.0)

24.4 (6.0)

24.4 (6.3)

24.9 (5.3)

 Missing = 236 (34.2%)

Smoking status, N (%)

 Never-smoker

56 (8.1)

25 (8.1)

17 (6.2)

14 (13.5)

 Former smoker ^b

407 (59.1)

157 (50.6)

181 (65.8)

69 (66.3)

 Current smoker

180 (26.1)

106 (34.2)

61 (22.2)

13 (12.5)

 Missing

46 (6.7)

22 (7.1)

16 (5.8)

8 (7.7)

Disease-related characteristics

Tumour histology, N (%)

 Adenocarcinoma

506 (73.4)

234 (75.5)

191 (69.5)

81 (77.9)

 Squamous cell carcinoma

134 (19.5)

55 (17.7)

61 (22.2)

18 (18.3)

 Large cell carcinoma

28 (4.1)

12 (3.9)

15 (5.5)

1 (1.0)

 Missing

21 (3.0)

9 (2.9)

8 (2.9)

4 (3.8)

NSCLC stage, N (%)

 III

91 (13.2)

40 (12.9)

36 (13.1)

15 (14.4)

 IV

528 (76.6)

238 (76.8)

207 (75.3)

83 (79.8)

 Missing

70 (10.2)

32 (10.3)

32 (11.6)

6 (5.8)

CNS metastasis, N (%)

82 (11.9)

47 (15.2)

27 (9.8)

8 (7.7)

PD-L1 expression, N (%)

 Negative (< 1%)

254 (36.5)

121 (39.0)

112 (40.7)

21 (20.2)

 Positive (1–49%)

178 (25.6)

78 (25.2)

70 (25.5)

30 (28.8)

 Strongly positive (> 50%)

185 (26.9)

75 (24.2)

65 (23.6)

45 (43.3)

 Missing

72 (10.4)

36 (11.6)

28 (10.2)

8 (7.7)

ECOG PS, N (%)

 0

236 (34.3)

122 (39.4)

85 (30.9)

29 (27.9)

 1

184 (26.7)

73 (23.5)

76 (27.6)

35 (33.7)

 2

79 (11.4)

29 (9.4)

30 (10.9)

20 (19.3)

 Missing

190 (27.6)

86 (27.7)

84 (30.5)

20 (19.2)

Comorbidities, N (%)

 COPD

287 (41.7)

130 (41.9)

119 (43.3)

38 (36.5)

Therapy-related characteristics

Treatment center, N (%)

 Haga Teaching Hospital

288 (41.8)

129 (41.6)

122 (44.4)

37 (35.6)

 LUMC

401 (58.2)

181 (58.4)

153 (55.6)

67 (64.4)

Previous lobectomy, N (%)

56 (8.1)

31 (10.0)

20 (7.3)

5 (4.8)

Previous radiotherapy, N (%)

332 (48.2)

164 (52.9)

129 (46.9)

39 (37.5)

Immuno-radiotherapy, N (%)

260 (37.7)

129 (41.6)

97 (35.3)

34 (32.7)

Line of therapy, N (%)

 1

452 (65.6)

182 (58.7)

184 (66.9)

86 (82.7)

 2

179 (25.9)

102 (32.9)

62 (22.5)

15 (14.4)

  ≥3

58 (8.4)

26 (8.3)

29 (10.5)

3 (2.9)

Immune checkpoint inhibitor, N (%)

 Pembrolizumab

420 (61.0)

172 (55.4)

170 (61.8)

78 (75.0)

 Nivolumab

118 (17.1)

57 (18.4)

46 (16.7)

15 (14.4)

 Atezolizumab

71 (10.3)

41 (13.2)

27 (9.8)

3 (2.9)

 Durvalumab

80 (11.6)

40 (12.9)

32 (11.6)

8 (7.7)

Chemo-immunotherapy c, N (%)

251 (36.4)

115 (37.1)

104 (37.8)

32 (30.8)

Duration of therapy, N (%)

 Single treatment

57 (8.2)

22 (7.1)

23 (8.4)

12 (11.5)

 2–90 days

241 (34.9)

104 (33.5)

107 (38.9)

30 (28.9)

 91–180 days

124 (17.9)

52 (16.8)

53 (19.2)

19 (18.3)

 181–365 days

114 (16.5)

54 (17.4)

42 (15.3)

18 (17.3)

  > 365 days

153 (22.2)

78 (25.2)

50 (18.2)

25 (24.0)